Clinical trials
Triple Negative Breast Neoplasms trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
95 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 2 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 7 |
| 2017 | 12 |
| 2018 | 7 |
| 2019 | 7 |
| 2020 | 10 |
| 2021 | 8 |
| 2022 | 8 |
| 2024 | 4 |
| 2025 | 8 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 38 |
| Active, not recruiting | 23 |
| Recruiting | 17 |
| Terminated | 15 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 10 |
| Novartis Pharmaceuticals | 10 |
| Merck Sharp & Dohme LLC | 8 |
| Hoffmann-La Roche | 5 |
| National Cancer Institute (NCI) | 5 |
| AbbVie | 4 |
| Bristol-Myers Squibb | 4 |
| Pfizer | 4 |
| Gilead Sciences | 3 |
| Seagen, a wholly owned subsidiary of Pfizer | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Triple Negative Breast Neoplasms | 95 |
| Breast Neoplasms | 35 |
| Carcinoma, Non-Small-Cell Lung | 26 |
| Ovarian Neoplasms | 22 |
| Squamous Cell Carcinoma of Head and Neck | 16 |
| Melanoma | 15 |
| Neoplasms | 14 |
| Stomach Neoplasms | 12 |
| Colorectal Neoplasms | 11 |
| Pancreatic Neoplasms | 11 |
Trials
Showing 1 to 25 of 95. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.